Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM   3:59:57 PM EDT
4.15
-0.12 (-2.81%)
Products

Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree® (Setmelanotide) For Use In Patients With Bardet-Biedl Syndrome

Published: 06/16/2022 20:37 GMT
Rhythm Pharmaceuticals Inc. (RYTM) - Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (setmelanotide) for Use in Patients With Bardet-biedl Syndrome.
Rhythm Pharmaceuticals - Imcivree Now Available for Chronic Weight Management in Adult and Pediatric Patients 6 Years of Age and Older.
Rhythm Pharmaceuticals - Also Announced That FDA Issued a Complete Response Letter for Snda for Setmelanotide in AlstrÖm Syndrome.
Rhythm Pharmaceuticals Inc - Plans to Reevaluate Potential Paths Forward in AlstrÖm Syndrome in U.S.rhythm Pharmaceuticals Inc - FDA Application for Imcivree Was Based on Data From Rhythm's Pivotal Phase 3 Clinical Trial.